|
Basic Characteristics of Mutations
|
|
Mutation Site
|
L52G |
|
Mutation Site Sentence
|
At the same time, for safety future clinical application, a mutant of HPV18 ofE6E7 fusion gene was generated by site-directed mutagenesis at L52G for the E6 protein and C98G for the E7 protein. |
|
Mutation Level
|
Amino acid level |
|
Mutation Type
|
Nonsynonymous substitution |
|
Gene/Protein/Region
|
E6 |
|
Standardized Encoding Gene
|
E6
|
|
Genotype/Subtype
|
HPV18 |
|
Viral Reference
|
-
|
|
Functional Impact and Mechanisms
|
|
Disease
|
-
|
|
Immune
|
- |
|
Target Gene
|
-
|
|
Clinical and Epidemiological Correlations
|
|
Clinical Information
|
- |
|
Treatment
|
- |
|
Location
|
- |
|
Literature Information
|
|
PMID
|
25227848
|
|
Title
|
A novel mutant of human papillomavirus type 18 E6E7 fusion gene and its transforming activity
|
|
Author
|
Zhou ZX,Zhao C,Li QQ,Zeng Y
|
|
Journal
|
Asian Pacific journal of cancer prevention : APJCP
|
|
Journal Info
|
2014;15(17):7395-9
|
|
Abstract
|
BACKGROUND: Persistent human papillomavirus (HPV) infection, especially with high-risk types such as HPV16 and HPV18, has been identified as the primary cause of cervical cancer. E6 and E7 are the major onco-proteins of high-risk HPVs, which are consistently expressed in HPV infected tissues but absent in normal tissues and represent ideal therapeutic targets for immunotherapy of cervical cancer. MATERIALS AND METHODS: In this study, the optimized fusion gene HPV18 E6E7 (HPV18 ofE6E7) was constructed according to genetic codon usage for human genes. At the same time, for safety future clinical application, a mutant of HPV18 ofE6E7 fusion gene was generated by site-directed mutagenesis at L52G for the E6 protein and C98G for the E7 protein. RESULTS: HPV18-E6E7 mutant (HPV18 ofmE6E7) constructed in this work not only lost the transformation capability for NIH 3T3 cells and tumorigenicity in BALB/c nude mice, but also maintained very good stability and antigenicity. CONCLUSION: These results suggest that the mutant should undergo further study for application as a safe antigen- specific therapeutic vaccine for HPV18-associated tumors.
|
|
Sequence Data
|
-
|